Abstract
Acquired pure red cell aplasia is a rare condition characterized by normocytic normochromic anemia with severe reticulocytopenia. In refractory acquired pure red cell aplasia, the low response rate of immunosuppressive therapy also constitutes a challenge. We herein report the case of a 58-year-old male with refractory acquired pure red cell aplasia that was successfully treated by eltrombopag at a dose of 75 mg/day. After application of eltrombopag, the patient achieved complete remission and tolerated the treatment very well, with only mild bilirubin elevation. These preliminary findings showed that eltrombopag may be effective and well tolerated in adult patients with refractory acquired pure red cell aplasia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Means RT Jr. Pure red cell aplasia. Blood. 2016;128(21):2504–9.
Xuemei Wu, Wang S, Xing-Yu Lu, Shen W, Qiao C, Yujie Wu, et al. Response to cyclosporine A and corticosteroids in adult patients with acquired pure red cell aplasia: serial experience at a single center. Int J Hematol. 2018;108:123–9.
Liu X, Xingyu Lu, Chen L, Xuemei Wu, Ruinan Lu, Wang S, et al. Immunosuppressive therapy for elderly-acquired pure red cell aplasia: cyclosporine A may be more effective. Ann Hematol. 2020;99(3):443–9.
Gill H, Wong RSM, Kwong YL. From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag. Ther Adv Hematol. 2017;8(5):159–74.
Olnes M, Scheinberg P, Calvo K, Desmond R, Tang Y, Dumitriu B, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11–9.
Gill H, Leung GM, Lopes D, Kwong YL. The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia. Br J Haematol. 2017;176(6):991–4.
Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818–25.
Sun H, Tsai Y, Nowak I, Liesveld J, Chen Y. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. Stem Cell Res. 2012;9(2):77–86.
Alvarado LJ, Huntsman HD, Cheng H, Townsley DM, Winkler T, Feng XM, et al. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ. Blood. 2019;133(19):2043–55.
Lengline E, Drenou B, Peterlin P, Tournilhac O, Abraham J, Berceanu A, et al. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Haematologica. 2018;103(2):212–20.
Huang Y, Jiang X, Han B. Effective treatment of refractory acquired pure red blood cell aplasia with eltrombopag and sirolimus: a case report. Ther Adv Hematol. 2020;11:2040620720940144.
Busca A, Dellacasa C, Giaccone L, Manetta S, Biale L, Godio L, et al. Eltrombopag for the treatment of refractory pure RBC Aplasia after Major ABO incompatible hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24:1765–70.
Dragani M, Andreani G, Familiari U, Marci V, Rege-Cambrin G. Pure red cell aplasia and amegakaryocytic thrombocytopenia in thymoma: the uncharted territory. Clin Case Rep. 2020;8:598–601.
Lum SH, Grainger JD. Eltrombopag for the treatment of aplastic anemia: current perspectives. Drug Des Devel Ther. 2016;10:2833–43.
Scheinberg P. Activity of eltrombopag in severe aplastic anemia. Hematol Am Soc Hematol Educ Program. 2018;2018:450–6.
Winkler T, Cooper JN, Townsley DM, Scheinberg P, Grasmeder S, Wu C, et al. Eltrombopag for refractory aplastic anemia: dosing regimens, long-term followup, clonal evolution and somatic mutation profiling. Blood. 2017;130(suppl 1):777.
Kim TO, Despotovic J, Lambert MP. Eltrombopag for use in children with immune thrombocytopenia. Blood Adv. 2018;2(4):454–61.
Funding
This study was supported by State Administration of Traditional Chinese Medicine Industry Specialty (No.201407001-4), National Public Health Grand Research Foundation (No.201202017), Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institute (No. JX10231801), and Project Funded by Jiangsu Provincial Special Program of Medical Science (No. BL2014086).
Author information
Authors and Affiliations
Contributions
All authors have made substantial intellectual contributions to this study. Guangsheng He performed study design and was involved in manuscript drafting and revision. Xiaoqing Liu collected and analyzed the data and drafted the manuscript. Lang Cheng, Yao He and Run Zhang collected and interpreted the data and helped write the manuscript. Ruinan Lu, Jianfu Zhang, Ming Hong and Jianyong Li revised the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Liu, X., Cheng, L., He, Y. et al. Eltrombopag restores erythropoiesis in refractory adult acquired pure red cell aplasia. Int J Hematol 114, 124–128 (2021). https://doi.org/10.1007/s12185-021-03100-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-021-03100-2